Vive - Kimera Exosomes
Vive by Kimera® Labs
MSC Exosome Growth Factor Cosmetic Product
Vive is a topical solution specially developed for cosmetic purposes. The product contains proteins, enzymes, growth factors, and exosomes derived from mesenchymal stem cells (MSCs).
Learn more about Exosomes.
Special Starter Kit:
- 3 Vials of 5mL Vive
- 25 Patient Trifolds
- 33×80″ Waiting Room Banner
- Inclusion in our patient referral database
Vive is a cell-free topical solution for professional use.
The MSC cell bank utilized in the manufacturing process is meticulously isolated from donated human placenta. The manufacturing process is performed following strict procedures.
When used topically, Vive may help by maintaining the skin’s vitality. Each vial of Vive (5ml) contains several billion exosomes that may help maintain skin texture and may create a glowing look.
Learn more at KimeraVive.com.
With Hyaluronic Acid, 16 Amino Acids, Vitamin C, Rose Water, plus Trehalose
I want to know more.
AN INVESTIGATIONAL PILOT STUDY by Dr. Greg Chernoff
THE UTILIZATION OF HUMAN PLACENTAL MESENCHYMAL STEM CELL DERIVED EXOSOMES AGING SKIN:
Forty patients were enrolled in a randomized, double-blinded, placebo (saline) controlled study. There were 20 patients in the treatment groupand 20 patients in the saline control group. Each group underwent facial micro-needling with immediate topical application of either 5 billion exosomes suspended in saline, or saline alone. Treatments were repeated at 30, 60,and 90 days, with final analysis at 120 days. Standardized photography was coupled with 3-dimensional analysis utilizing the Quantificare Imaging System. Linear analog tests were also administered to objectify patient satisfaction.
There were no adverse reactions, allergic, or hypersensitivity reactions reported. The exosome treatment group showed improved tone, quality, and clarity of their skin compared to the control group (p < .0001), with a reduction in pores, pigment, oiliness, and improvement in evenness of skin. There was a constant progression of satisfaction with results in the treatment group from 30 to 120 days, compared with a high degree of dissatisfaction with results in the control group.